(TOI) Oncology Institute - Ratings and Ratios

The Oncology Institute, Inc. is a US-based oncology company delivering comprehensive cancer care services across the country. With a robust business model, the company operates through three key segments: Dispensary, Patient Services, and Clinical Trials & Other, effectively catering to the diverse needs of adult and senior cancer patients.

Through its diverse offerings, the company provides physician services, in-house infusion and dispensary, clinical trials, radiation, outpatient blood product transfusion, and patient support services. Additionally, it offers educational seminars, support groups, counseling services, and 24/7 patient assistance, showcasing a patient-centric approach. The companys expertise extends to managing clinical trials, palliative care programs, and stem cell transplants, often in collaboration with pharmaceutical and medical device companies.

Given the companys operational segments and services, its clear that TOI is positioned to capitalize on the growing demand for cancer care services. With a strong presence in the US market, the company is well-placed to benefit from the increasing prevalence of cancer diagnoses and the subsequent need for comprehensive care. The companys diversified revenue streams, including clinical trials and patient services, provide a degree of stability and potential for growth.

Analyzing the , the stocks recent price action indicates a potential short-term consolidation phase, with the last price at $2.55 and SMA20 at $2.61. The stock is above its SMA50 and SMA200, indicating a longer-term uptrend. The ATR suggests a relatively high volatility of 14.74%. Considering the , the companys Market Cap stands at $245.73M USD, with a negative P/E and P/E Forward, indicating that the company is currently unprofitable. The negative RoE of -272.61 further highlights the companys current financial challenges.

Forecasting the stocks performance based on the and , its likely that TOI will experience continued volatility in the short term. However, if the company can demonstrate progress in its clinical trials and patient services segments, potentially leading to improved financial performance, the stock may be poised for a longer-term uptrend. A potential price target could be around $3.50, representing a 37% increase from the current price, driven by improved financials and a sustained uptrend. Conversely, failure to address current financial challenges could lead to further declines, potentially testing the $2.00 level.